DarioHealth has bought fellow digital health specialist Twill for $10 million upfront, plus another 10 million in stock worth upwards of $20 million, in a move that combin
Novo Nordisk is leaving nothing to chance when it comes to claiming a stake in the burgeoning market for diabetes and obesity therapies, announcing a plan to spend a whopp
When digital health giants Teladoc and Livongo announced their $18.5 billion merger, shares in both companies fell sharply as investors tried to work out the rationale for the
Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals i
South Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Takeda that will expand its expertise with small mol
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh